Quick Facts: Refresh Tears

• Relief Domain: May offer temporary relief of sensations like burning, irritation, and general discomfort associated with eye dryness.
• Symptom Management: An option for addressing symptoms linked to environmental factors, such as wind or sun exposure.
• Protective Use: May be used as a protectant against the recurrence of minor eye irritation.

Refresh Tears is a product indicated for ophthalmic use to help manage symptoms related to a lack of natural lubrication in the eye. It may offer temporary relief of discomfort, irritation, and burning sensations caused by conditions like dryness of the eye or exposure to external factors such as wind. The formulation may support the moisture level on the eye’s surface, contributing to increased comfort.

This product is used as a protectant to potentially reduce the likelihood of further irritation or to help relieve existing dryness.

It may be applied as needed to the affected eye(s) to support patient well-being by addressing temporary ocular discomfort and promoting a comfortable state.

The eligibility for using Refresh Tears (Carboxymethylcellulose Sodium) is determined by its status as an Over-The-Counter (OTC) topical ophthalmic lubricant, which is not significantly absorbed into the body. This non-systemic nature results in minimal population restrictions in regulatory labeling.

Eligibility Scope

Eligibility Classifications

The most critical restriction is the absolute contraindication for hypersensitivity to ingredients, a standard rule for nearly all medications. Otherwise, the medicine is classified as permitted for use across most demographics, including pregnant and breastfeeding individuals, as its effect is local to the eye and does not rely on systemic activity.

Interactions with other medicines and products

The official regulatory profile for Carboxymethylcellulose Sodium Ophthalmic Solution is characterized by its topical administration and negligible systemic absorption of the active ingredient. This low level of systemic exposure is the determining factor in how regulatory bodies define the product’s official interaction information.

Systemic Interaction Status

Governmental prescribing information and drug labels do not document any drug–drug, drug–food, or drug–alcohol interactions with systemic medicines or substances. Due to the lack of significant plasma exposure, interactions involving metabolic enzymes (pharmacokinetic interactions) or pharmacodynamic effects with orally administered medications are not listed in official regulatory labeling. Consequently, the product label does not specify any combinations as formally contraindicated based on systemic interaction risk.

Administration-Timing Interference

The only officially documented interaction pattern relates strictly to a local physico-chemical interference on the eye’s surface. This interference results in specific administration-timing rules for co-use with other local ophthalmic treatments:

• Topical Ophthalmic Products: When administered with any other topical ophthalmic medicinal product, a mandatory separation interval must be observed between applications to ensure the lubricant does not physically compromise the contact time of the second medicine.
• Order of Application: Ophthalmic solutions must be administered before ophthalmic ointments to ensure the solution achieves proper contact time with the ocular surface.

This interaction structure reflects a necessary procedural constraint defined in regulatory documents.

The active ingredient, carboxymethylcellulose ( CMC), functions as a lubricating agent by supplementing the tear film. CMC molecules are water-soluble polymers that increase the viscoelasticity and residence time of the tear film on the corneal and conjunctival epithelia, resisting gravitational flow and evaporative forces. This mechanism results in a reduction of the coefficient of friction between the eyelid and the corneal surface and promotes tear film continuity and stability across the air-cornea interface. The CMC is designed to enhance surface wetting properties due to its mucomimetic characteristics, contributing to a stable layer of lubrication. This is a result of enhanced film viscosity.

How to Use Refresh Tears

Administration of this ophthalmic solution follows standard instructions for use. The product is for topical ophthalmic use only.

Dosing and Frequency

Required Procedural Steps

Before initial use, check that the tape seals on the top and bottom flaps are intact and the solution has not changed color or become cloudy. Contamination prevention is critical: wash hands before use and do not touch the tip of the container to the eye or any other surface. This ensures the sterility of the product as required for ophthalmic solutions.

To administer, gently pull down the lower eyelid to form a small pouch. After instilling the drop(s), close the eye gently for one to two minutes, and immediately replace the cap tightly. If administering other eye medications, wait at least five minutes between applications, and use eye drops before any eye ointments. The product must be discarded 90 days after opening and stored at room temperature.

Refresh Tears: Recent Clinical Evidence

Clinical evidence for lubricant eye drops, such as those containing Carboxymethylcellulose (CMC), primarily focuses on their use in managing symptoms of dry eye disease (DED). CMC acts as a viscosity agent, designed to increase the residence time of the solution on the ocular surface.

Research has evaluated the effectiveness of CMC solutions, particularly at concentrations of 0.5% to 1.0%, in comparison to placebo and other commercially available lubricating agents.

Efficacy Studies

Studies measured changes in key dry eye indicators following the regular administration of CMC solutions:

• Ocular Surface Disease Index (OSDI): Trials commonly use the OSDI questionnaire, which measures symptom severity, including dryness, grittiness, and blurred vision. Research has reported improvement in OSDI scores from baseline.
• Tear Film Break-up Time (TFBUT): TFBUT, a measure of tear film stability, has been assessed in several studies. Findings generally indicate a temporary, statistically significant increase in TFBUT, suggesting improved tear film stability.
• Corneal and Conjunctival Staining: Research has evaluated these measures, which indicate damage to the surface of the eye. Improvement in staining scores has been noted in studies over periods typically ranging from four to twelve weeks.

Safety and Tolerability

The overall safety profile of CMC-based eye drops is considered favorable. The most frequently reported adverse events are mild and transient, including temporary blurring of vision or slight ocular irritation immediately following application. Discontinuation rates due to adverse events are typically low across the treatment groups in most trials, indicating good tolerability during short-term and sustained use.

Common questions about Refresh Tears (FAQ)

Q: Is it safe to use this medicine for a long time?

Official regulatory documents state that antiepileptic drugs, including this medication, were associated with an increased risk of suicidal thoughts or behavior during clinical trials. The official product information indicates that if the medication is discontinued, a gradual dose reduction over a minimum of one week is typically recommended to minimize the potential risk for withdrawal symptoms or seizures. This gradual approach helps ensure safety when stopping treatment.

Q: Can children under 4 years old use this product?

According to the official product labeling, this medication is approved as adjunctive therapy for partial-onset seizures in pediatric patients 1 month of age and older. For other conditions, such as diabetic nerve pain, postherpetic neuralgia, or fibromyalgia, the medication's approved labeling does not include use in pediatric patients under 18 years of age.

How to Store and Dispose of Refresh Tears?

Official labeling requires the storage of Refresh Tears Lubricant Eye Drops between 15 C and 30 C (59 F and 86 F), and the product must be protected from freezing. The medicine must be kept out of the reach of children.

Stability and Handling

To maintain product integrity, the container should be kept tightly closed. If the solution changes color or becomes cloudy, it must be discarded immediately. For multi-dose bottles, the contents should be discarded 90 days after opening.

Disposal

Expired or unused product should not be poured down a sink or toilet. Consumers should consult a pharmacist or healthcare professional for guidance on the proper method for discarding the medication.